Kaneka (TSE:4118) Stock Can Margin Gains Justify Its Low P/E

Kaneka came into this quarter with the stock already grinding higher, up about 18% over three months and closing at ¥6,314 today, and a reputation as a steady chemicals compounder on a modest P/E of 10.6x. The headline this time is margins. Q1 FY2027 revenue of ¥223,025m sits against net income of ¥8,941m, and trailing net profit margin stands at 4.3%, helped by a very large one off gain of ¥12.0b in the past year.

Is Kaneka trading at a genuine discount, or do the headline margins and one off gain simply make the stock look cheaper than it is on 10.6x P/E? See how the current share price compares with a fair value range in the full valuation analysis for Kaneka

Q1 2027 Earnings Summary

• Revenue (Q1 2027 vs. Q1 2026): ¥223,025m vs. ¥198,682m (up 12.3%)
• Net Income (Excl. Extra Items, Q1 2027 vs. Q1 2026): ¥8,941m vs. ¥4,261m (up 109.9%)
• Basic EPS (Q1 2027 vs. Q1 2026): ¥148.45 vs. ¥67.73 (up 119.1%)
• Trailing 12M Net Profit Margin (FY 2027 Q1 TTM vs. FY 2026 Q1 TTM): 4.3% vs. 2.8% (margin higher year over year)

Prefer clean charts instead of another wall of earnings tables and ratios for Kaneka? Get a full visual breakdown of the company, with an at-a-glance view of its valuation set out clearly in the company report for Kaneka.

Kaneka earnings skew positive for diversified story

For investors leaning positive on Kaneka as a diversified industrial with some higher value pockets, this quarter helps the story. Revenue of ¥223,025m and net income of ¥8,941m are both above the prior year period. That supports the idea that the broad portfolio is pulling in the same direction rather than relying on a single segment. The higher trailing net margin of 4.3% compared with 2.8% a year earlier also fits a view that earnings quality is improving beyond the large one off gain booked in the past year.

Short term bear arguments lose some edge

Bears often focus on low margins and the risk that complex portfolios disguise weak core earnings. The latest Kaneka numbers soften that case a little. Revenue and net income are higher than Q1 2026, and earnings per share has more than doubled, even before considering the one off gain in the trailing period. The share repurchase program reported on 1 July 2026 also points to an active capital return framework. None of this removes structural concerns about cyclical chemicals, but near term financial stress looks less acute than that narrative implies.

After one-off gains and a dividend that free cash flow does not fully cover, review our independent risk analysis for Kaneka which shows 3 important warning signs to expose any deeper vulnerabilities.

Stay Ahead With Simply Wall St

If Kaneka's mix of modest P/E and improving reported margins has your attention, register for free with Simply Wall St and add it to a Watchlist to track its share price against fair value and spot a potential entry point. Once you own it, use the Portfolio Command Center to cut through the noise and focus on the key developments that matter for your holdings. For a longer term view, tap into crowd wisdom through the Community and see how other investors are thinking about catalysts and risks. By surfacing those turning points early, you give yourself a better chance to stay ahead of the market.

Seeking Alternatives Beyond Kaneka?

Fresh ideas can move fast. Some stocks are building quiet momentum, while others are dropping off the radar. Scan these curated shortlists before the crowd and consider your options.

• Spot potential breakout plays with solid balance sheets before the stories start flying by using the curated list of solid balance sheet and fundamentals stocks (41 results).
• Explore income ideas that might help keep your portfolio cash flow working harder through the hand picked 33 dividend fortresses.
• Hunt for early stage opportunities that could shift sentiment quickly by checking the filtered 69 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com